featured
ASCO 2015 Recap: The Case for Changing the Class of Systemic Agent for Disease Progression or Intolerance of First-Line Therapy—Part 3
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.